ArticleFrontiers in pediatrics2026
Adolescent Epstein-Barr virus-associated cholestatic jaundice with porta hepatis/pancreatic head lymphadenopathy and transient CA 19-9 elevation: a case report.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cholestatic jaundice is uncommon in adolescents. Epstein-Barr virus (EBV)-related inflammatory lymphadenopathy can mimic malignant biliary obstruction and cause a transient rise in carbohydrate antigen 19-9 (CA 19-9), complicating diagnosis. Case presentation: A previously healthy 15-year-old girl presented with 6 days of jaundice and dark urine without fever. Physical examination showed moderate generalized jaundice with mild scleral icterus; multiple mobile, non-tender lymph nodes in the bilateral cervical regions and right post-auricular area (largest ∼2 × 2 cm); palpable liver and spleen; and mild right upper-quadrant tenderness with equivocal Murphy's sign. Initial tests showed a cholestatic pattern (total/direct bilirubin 102.4/67.7 μmol/L at the referring hospital; and 133.2/126.3 μmol/L on admission) with elevated ALP/GGT and total bile acids. CT suggested a porta hepatis-to-pancreatic-head soft-tissue density with mild intrahepatic ductal prominence; CA 19-9 was 117.7 U/mL [ref <37 U/mL]. EBV POCT was positive; EBV DNA was detected at low level. MRI/MRCP (2025-09-29) showed no obvious biliary obstruction. After MRCP excluded fixed biliary obstruction, the patient improved with conservative management (diagnostic evaluation, close monitoring, and symptom-directed care) without invasive intervention; CA 19-9 declined. No causal inference regarding any medication effect should be drawn, and we do not recommend self-medication or routine off-label/unlicensed use of cholestasis-directed agents for EBV infection. In immunocompetent hosts, EBV-related lymphadenopathy is usually self-limited, and this case does not represent EBV-associated lymphoproliferative disease. Conclusion: EBV-related cholestatic hepatitis in adolescents can present with transient CA 19-9 elevation and reactive porta hepatis/pancreatic head lymphadenopathy, mimicking malignant obstruction. Serial laboratory and imaging assessments-particularly MRCP-together with conservative management may obviate unnecessary invasive procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.